TRIPTORELIN

Summary

Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist, available as long-acting depot/embonate formulations, and is an FDA-prescription drug used for hormone-responsive conditions ^[1,2]. In advanced prostate cancer, depot formulations achieve and maintain castrate testosterone levels in the large majority of patients (over 90% maintained castration with the 6-month formulation), are generally well tolerated, and improve quality of life and cost via slow-release dosing ^[2,4]. For endometriosis, clinical studies demonstrate efficacy in improving pain symptoms and reducing endometriotic nodule volume ^[1]. In children with central precocious puberty, triptorelin depot suppresses the pituitary-gonadal axis and pubertal development, with quarterly and monthly formulations giving similar results and no reported long-term adverse effects on reproductive function, though some questions on hyperandrogenism/PCOS risk remain to be clarified ^[3]. The human evidence base across multiple indications is well established.

Sources

1. 1. Triptorelin for the treatment of endometriosis Expert opinion on pharmacotherapy, 2014.
2. 2. Triptorelin embonate (6-month formulation) Drugs, 2010.
3. 3. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty Expert review of clinical pharmacology, 2018.
4. 4. Triptorelin in the management of prostate cancer Future oncology (London, England), 2013.

For educational purposes only.